Haima Therapeutics is a pre-clinical stage biotechnology company.
Haima Therapeutics is a pre-clinical stage biotechnology company. It focused on developing bio-inspired therapies for the treatment of bleeding and other blood-related ailments. It is developing platelet-inspired therapeutics to mitigate bleeding and treat other blood-related disorders where platelets play a key role in its progressions, such as thrombosis, inflammation, and cancer.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 16, 2020 | Grant | $0.94M | 1 | National Science Foundation | — | Detail |
Jun 15, 2019 | Grant | $300K | 1 | National Institutes of Health | — | Detail |
Jan 1, 2018 | Grant | $225K | 1 | National Science Foundation | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Science Foundation | Yes | Grant |
National Institutes of Health | Yes | Grant |